MondegarAI
Avidity Partners Management LP

Q3 2025 · 13F-HR

Avidity Partners Management LPholdings as filed

Filed 2025-11-14 · accession 0001791827-25-000008

$439.4M
Reported value
43
Positions
2025-09-30
Period end
View analyzed profile →PRO

The Brief · Avidity Partners Management LP · Q3 2025

AI · grounded in 13F

Avidity Partners Management LP established a new position in Dianthus Therapeutics Inc DNTH valued at $126.1M. The fund also initiated a new stake in CG Oncology Inc CGON for $64.5M. Other new additions include Medtronic PLC MDT at $18.2M and Boston Scientific Corp BSX at $16.0M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
252828108DNTHDIANTHUS THERAPEUTICS INC$126.1M28.7%3,204,184CommonSOLE
156944100CGONCG ONCOLOGY INC$64.5M14.7%1,600,899CommonSOLE
G5960L103MDTMEDTRONIC PLC$18.2M4.13%190,600CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$16.0M3.65%164,300CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$12.7M2.89%660,424CommonSOLE
110122108BMYBRISTOL-MYERS SQUIBB CO$11.6M2.64%257,600CommonSOLE
632307104NTRANATERA INC$11.3M2.58%70,400CommonSOLE
235851102DHRDANAHER CORPORATION$10.8M2.47%54,700CommonSOLE
881624209TEVATEVA PHARMACEUTICAL INDS LTD$10.3M2.34%510,000CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$10.3M2.34%2,994,033CommonSOLE
008064206JBIOJADE BIOSCIENCES INC$9.7M2.21%1,127,186CommonSOLE
717081103PFEPFIZER INC$9.3M2.12%366,400CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$9.2M2.09%18,900CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$8.7M1.98%8,981,855CommonSOLE
372303206GMABGENMAB A/S$7.6M1.73%248,100CommonSOLE
59267L107METSERA INC$7.4M1.67%140,500CommonSOLE
91324P102UNHUNITEDHEALTH GROUP INC$6.1M1.40%17,800CommonSOLE
04335A105ARVNARVINAS INC$6.0M1.35%698,363CommonSOLE
03073E105CORCENCORA INC$5.9M1.35%19,000CommonSOLE
29261A100EHCENCOMPASS HEALTH CORP$5.3M1.21%41,900CommonSOLE
478160104JNJJOHNSON & JOHNSON$5.0M1.13%26,800CommonSOLE
125523100CITHE CIGNA GROUP$4.8M1.09%16,600CommonSOLE
00287Y109ABBVABBVIE INC$4.6M1.04%19,800CommonSOLE
58155Q103MCKMCKESSON CORP$4.5M1.02%5,800CommonSOLE
14280C105CARLCARLSMED INC$4.3M0.98%321,912CommonSOLE
49177J102KVUEKENVUE INC$4.3M0.98%265,200CommonSOLE
4525EP101VTLUSDIMMUNIC INC$4.1M0.94%4,699,411CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$4.0M0.92%214,400CommonSOLE
30063P105EXKEXACT SCIENCES CORP$4.0M0.92%73,600CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$3.6M0.82%306,000CommonSOLE
759916109RGENREPLIGEN CORP$3.1M0.71%23,300CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$3.1M0.70%144,000CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$2.9M0.66%14,500CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$2.9M0.65%140,300CommonSOLE
07373V105BEAMBEAM THERAPEUTICS INC$2.7M0.62%112,000CommonSOLE
811292200SCYXSCYNEXIS INC$2.6M0.59%3,350,528CommonSOLE
42226A107HQYHEALTHEQUITY INC$2.4M0.55%25,300CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$2.2M0.50%297,500CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$2.1M0.49%53,400CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$1.9M0.44%40,500CommonSOLE
457669307INSMINSMED INC$1.7M0.38%11,600CommonSOLE
48576U205KPTIKARYOPHARM THERAPEUTICS INC$880,0620.20%134,566CommonSOLE
45254E107IMRXIMMUNEERING CORP$636,3000.14%90,900CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.